Sponsored Links

BARDA Awards Up To $143 Million For Advanced Development Of A New Drug To Treat Anthrax PDF Print E-mail
Medical News - Bio-terrorism
The HHS Biomedical Advanced Research and Development Authority (BARDA) awarded a contract to Elusys Therapeutics, Inc. of Pine Brook, N.J., for the advanced development of a medication to treat inhalational anthrax, one of the top bioterrorism threats facing the nation. The first year of the contract, called the base year, is valued at $16.8 million...

Read more: Bio-terrorism / Terrorism News From Medical News Today